TENAYA THERAPEUTICS I

Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference

02 Aug 2023 13:05:02 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

10 May 2023 13:19:57 By Nasdaq GlobeNewswire

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

03 May 2023 05:00:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

02 May 2023 04:50:18 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

21 Apr 2023 13:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

08 Mar 2023 13:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

07 Feb 2023 14:17:05 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

09 Jan 2023 04:00:02 By Nasdaq GlobeNewswire

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

07 Dec 2022 13:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

28 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

23 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Closing of Public Offering

21 Nov 2022 14:45:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Public Offering

16 Nov 2022 21:39:47 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Proposed Public Offering

16 Nov 2022 13:01:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

10 Nov 2022 13:05:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

04 Nov 2022 05:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

04 Oct 2022 05:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

29 Sep 2022 05:00:01 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

29 Sep 2022 04:45:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

06 Sep 2022 13:05:00 By Nasdaq GlobeNewswire